A case report involving cosyntropin was published on September 18, 2026. The publication, titled "Case Report: Tislelizumab-associated secondary adrenal insufficiency in a patient with lung squamous cell carcinoma," appeared in Frontiers in Endocrinology.
The report describes a case concerning a patient with lung squamous cell carcinoma who experienced secondary adrenal insufficiency associated with tislelizumab treatment. Cosyntropin is referenced in connection with this case report.
No findings, outcomes, or efficacy data from the publication are detailed here. This brief reports only that the case report exists and was published in the stated journal on the stated date.
Readers interested in cosyntropin's approved uses and background can consult the compound overview for additional context.